Cannabinoids

Cannabidiol shows sustained effects against depression for seven days

A recent study found that a single dose of cannabidiol in rats with symptoms of depression was highly effective, eliminating the symptoms on the same day and maintaining the beneficial effects for a week. The findings reinforce those of prior research showing that cannabidiol, a component of Cannabis sativa, the plant most commonly used to

Cannabis extract helps reset brain function in psychosis

Research from King’s College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psychosis. Results from a new MRC-funded trial, published in JAMA Psychiatry, provide the first evidence of how cannabidiol acts in the brain to reduce psychotic symptoms. Cannabidiol, also referred to

World’s Only Hops-Derived CBD Product

Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that it has garnered global news coverage in Westword newspaper and other outlets for its partnership with Peak Health to distribute the first-ever, and only, hops (Kriya brand Humulus)-derived cannabidiol (CBD) product ImmunAg™. “We are honored to have our Real

World-Renowned Neurosurgeon, Health and Nutrition Expert, Dr. Joseph Maroon, Joins CV Sciences, Inc. Board of Directors

CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”) is pleased to announce the appointment of Joseph Maroon, MD, FACS (“Dr. Maroon”), to its Board of Directors. Dr. Maroon is a clinical professor and vice chairman of the Department of Neurological Surgery and the Heindl Scholar in Neuroscience at the University of Pittsburgh Medical

Cannabinoids, The Heart of the Matter

GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences’ own Chief Science Officer, Dr. Andrea Small-Howard, joins